Featured Research

from universities, journals, and other organizations

Higher healing rate using unique cell-based therapy in chronic venous leg ulcers

Date:
August 2, 2012
Source:
University of North Carolina School of Medicine
Summary:
A new study finds that treating chronic venous leg ulcers with a topical spray containing a unique living human cell formula provides a 52 percent greater likelihood of wound closure than treatment with compression bandages only.

Treating chronic venous leg ulcers with a topical spray containing a unique living human cell formula provides a 52 percent greater likelihood of wound closure than treatment with compression bandages only.

That's the conclusion of a new study conducted in part at the University of North Carolina School of Medicine and published online by The Lancet this week.

The Phase II clinical trial, which investigates the efficacy of HP802-247 from Healthpoint® Biotherapeutics, was designed to determine effectiveness of certain cell concentrations and dosing frequencies of HP802-247, when combined with standard care in treatment of chronic venous leg ulcers.

William Marston, MD, professor of surgery in the UNC School of Medicine and medical director of the UNC Wound Healing Clinic, is an investigator in the study and one of the article authors.

Venous leg ulcers are caused by impaired circulation in the vein system of the legs from blockages or damage. Typically, venous leg ulcers become chronic wounds if, after three months of standard treatment, they fail to heal. Chronic venous leg ulcers appear as open lesions and need specialized medical care. An estimated 1-2 million Americans suffer from venous leg ulcers.

HP802-247 is a living human cell formula consisting of skin cells (keratinocytes and fibroblasts), which release growth factors into the wound on a cellular level for tissue regeneration, along with fibrinogen, which forms a "cellular web" for blood clotting and elasticity. During the study, 228 patients were enrolled at 28 medical centers in the United States, including UNC. Two different cell concentrations and two separate dosing frequencies were tested with standard care, in addition to a control group, over a 12-week period.

Dr. Marston says, "In the past, some chronic venous leg ulcers were treated with skin grafts, which occasionally could break down and also required the patient to heal a partial thickness wound at the skin graft harvest site. During this study, unique living cells were sprayed on the patient's wound, which interacted with the patient's cells for improved wound healing."

"In the study, we determined the best dosing of the fibroblast/keratinocyte preparation that markedly accelerated the rate of healing of the wounds. We are currently preparing a Phase III pivotal trial to start late this year," adds Dr. Marston.

The study was funded by Healthpoint® Biotherapeutics.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert S Kirsner, William A Marston, Robert J Snyder, Tommy D Lee, D Innes Cargill, Herbert B Slade. Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 2012; DOI: 10.1016/S0140-6736(12)60644-8

Cite This Page:

University of North Carolina School of Medicine. "Higher healing rate using unique cell-based therapy in chronic venous leg ulcers." ScienceDaily. ScienceDaily, 2 August 2012. <www.sciencedaily.com/releases/2012/08/120802183750.htm>.
University of North Carolina School of Medicine. (2012, August 2). Higher healing rate using unique cell-based therapy in chronic venous leg ulcers. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/08/120802183750.htm
University of North Carolina School of Medicine. "Higher healing rate using unique cell-based therapy in chronic venous leg ulcers." ScienceDaily. www.sciencedaily.com/releases/2012/08/120802183750.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins